CXCL12 and diabetic kidney disease: First, although the experimental data are conflicting [90], it is possible that potentiation of SDF-1 by DPP-4 inhibitors may enhance the inflammatory and proliferative responses to kidney injury and may thereby aggravate the course of diabetic nephropathy [27, 28].